IGN is happy to announce that Ayala has made some major announcements on the horizon for the upcoming year, including an initial round of funding for a Phase III study of its new Vanda® drug.The company says the new Phase III trial is designed to test Vanda as an adjunct to the standard of care […]

Continue Reading...